The COVID-19 Wave Was Already Here: High Seroprevalence of SARS-CoV-2 Antibodies Among Staff and Students in a Cameroon University
Overview
Authors
Affiliations
Background: Seroprevalence studies, to estimate the proportion of people that has been infected by SARS-CoV-2 are importance in African countries, where incidence is among the lowest in the world.
Objective: This study aimed at evaluating the exposure to SARS-CoV-2 within a university setting of Cameroon.
Methods: A cross-sectional study performed in December 2020 - December 2021, among students and staffs of the Evangelical University of Cameroon. COVID-19 antigen rapid detection test (RDT) was performed using Standard Q Biosensor, and one year after SARS-CoV-2 antibody-test was performed within the same population using RDT and chemiluminescence immunoassay (CLIA).
Results: 106 participants were enrolled (80% students), female sex was the most represented. Positivity to SARS-CoV-2 was 0.0% based on antigen RDTs. The seroprevalence of SARSCoV- 2 antibodies was estimated at 73.6% (95% CI. 64.5-81.0) for IgG and 1.9% (95% CI. 0.2-6.8) for IgM/IgG with RDTs, and 91.9% (95% CI. 84.7-96.4) for anti-nucleocapsid with CLIA. 95.3% (101) reported having developed at least one of the known COVID-19 symptoms (cough and headache being the most common). 90.3% (28) of people who experienced at least one of these symptoms developed IgG antibodies. 40.6% (43) of participants took natural herbs, whereas 55.7% (59) took conventional drugs. The most used herb was , while the most used drugs were antibiotics.
Conclusion: In this Cameroonian University community, SARS-CoV-2 seroprevalence is high, with a greater detection using advanced serological assays. This indicates a wide viral exposure, and the need to adequate control measures especially for those experiencing any related COVID-19 symptoms.
Traore B, Guindo M, Konate D, Kane F, Incandela N, Traore A Influenza Other Respir Viruses. 2024; 18(7):e13343.
PMID: 39044355 PMC: 11300109. DOI: 10.1111/irv.13343.
Moguem Soubgui A, Ndeme Mboussi W, Foko L, Embolo Enyegue E, Koanga Mogtomo M PLOS Glob Public Health. 2024; 4(2):e0002380.
PMID: 38346064 PMC: 10861046. DOI: 10.1371/journal.pgph.0002380.
Essomba R, Bayibeki A, Lissom A, Ateba P, Seni N, Fouda C Influenza Other Respir Viruses. 2023; 17(11):e13222.
PMID: 37964992 PMC: 10640965. DOI: 10.1111/irv.13222.